Scarica l'app Stockscreener
0.6612
2.69%
0.0173
Dopo l'orario di chiusura:
.65
-0.0112
-1.69%
Precedente Chiudi:
$0.6439
Aprire:
$0.6348
Volume 24 ore:
3.09M
Relative Volume:
0.18
Capitalizzazione di mercato:
$160.46M
Reddito:
$424.90K
Utile/perdita netta:
$-94.02M
Rapporto P/E:
-0.2662
EPS:
-2.4842
Flusso di cassa netto:
$-51.25M
1 W Prestazione:
+1.88%
1M Prestazione:
-42.50%
6M Prestazione:
+48.58%
1 anno Prestazione:
-33.88%
Intervallo 1D:
$0.626
$0.67
Intervallo di 1 settimana:
$0.621
$0.6962
Portata 52W:
$0.1611
$2.5375
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.6612 | 156.26M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics CEO discusses LYTENAVA commercial launch - Investing.com
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Canada
Only one FDA-approved eye medicine of its type exists in the U.S. It’s LYTENAVA. - Stock Titan
OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits
AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics Stock Price Forecast. Should You Buy OTLK? - StockInvest.us
People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - biobuzz.io
CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan
Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - Stock Titan
Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - VisionMonday.com
Outlook Therapeutics appoints Kevin Lundquist as CFO as Lawrence Kenyon to depart - TradingView
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference - marketscreener.com
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView
Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Outlook Therapeutics delays quarterly SEC filing - TipRanks
META_TITLE_QUOTE - Yahoo Finance
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - moomoo.com
Outlook Therapeutics, Inc. SEC Filing (Aug 17, 2026) | OTLK NT 10-Q - Stock Titan
Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - VisionMonday.com
symbol__ Stock Quote Price and Forecast - CNN
Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey
MSN Money - MSN
Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0 - Investing.com South Africa
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet - Yahoo Finance
Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear - simplywall.st
Outlook Therapeutics CFO Kenyon acquires 101,010 shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants - Stock Titan
Outlook Therapeutics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:OTLK) 2026-08-14 - Seeking Alpha
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares By Investing.com - Investing.com Australia
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):